These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26512410)

  • 1. G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges.
    Ritter K; Buning C; Halland N; Pöverlein C; Schwink L
    J Med Chem; 2016 Apr; 59(8):3579-92. PubMed ID: 26512410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges.
    Li Z; Xu X; Huang W; Qian H
    Med Res Rev; 2018 Mar; 38(2):381-425. PubMed ID: 28328012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119.
    Kang SU
    Drug Discov Today; 2013 Dec; 18(23-24):1309-15. PubMed ID: 24060477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic application of GPR119 ligands in metabolic disorders.
    Yang JW; Kim HS; Choi YW; Kim YM; Kang KW
    Diabetes Obes Metab; 2018 Feb; 20(2):257-269. PubMed ID: 28722242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [GPR119 Receptor Agonists: Characteristics, Physiological Role, Prospects of Use in the Treatment of Diabetes Mellitus Type 2 and Metabolic Syndrome].
    Tyurenkov IN; Kurkin DV; Bakulin DA; Lomkina EM; Volotova EV
    Usp Fiziol Nauk; 2015; 46(4):28-37. PubMed ID: 27183782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapeutic potential of GPR119 agonists for type 2 diabetes.
    Ohishi T; Yoshida S
    Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders.
    Shah U; Kowalski TJ
    Vitam Horm; 2010; 84():415-48. PubMed ID: 21094910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders.
    Shah U
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):519-32. PubMed ID: 19562648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GPR119 agonists for the treatment of type 2 diabetes.
    Jones RM; Leonard JN; Buzard DJ; Lehmann J
    Expert Opin Ther Pat; 2009 Oct; 19(10):1339-59. PubMed ID: 19780700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery, optimisation and in vivo evaluation of novel GPR119 agonists.
    Brocklehurst KJ; Broo A; Butlin RJ; Brown HS; Clarke DS; Davidsson Ö; Goldberg K; Groombridge SD; Kelly EE; Leach A; McKerrecher D; O'Donnell C; Poucher S; Schofield P; Scott JS; Teague J; Westgate L; Wood MJ
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7310-6. PubMed ID: 22061639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases?
    Cornall LM; Mathai ML; Hryciw DH; McAinch AJ
    Expert Opin Investig Drugs; 2013 Apr; 22(4):487-98. PubMed ID: 23442069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A categorical structure-activity relationship analysis of GPR119 ligands.
    Kumar P; Carrasquer CA; Carter A; Song ZH; Cunningham AR
    SAR QSAR Environ Res; 2014; 25(11):891-903. PubMed ID: 25401513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119.
    Wacker DA; Wang Y; Broekema M; Rossi K; O'Connor S; Hong Z; Wu G; Malmstrom SE; Hung CP; LaMarre L; Chimalakonda A; Zhang L; Xin L; Cai H; Chu C; Boehm S; Zalaznick J; Ponticiello R; Sereda L; Han SP; Zebo R; Zinker B; Luk CE; Wong R; Everlof G; Li YX; Wu CK; Lee M; Griffen S; Miller KJ; Krupinski J; Robl JA
    J Med Chem; 2014 Sep; 57(18):7499-508. PubMed ID: 25208139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biased signaling of lipids and allosteric actions of synthetic molecules for GPR119.
    Hassing HA; Fares S; Larsen O; Pad H; Hauge M; Jones RM; Schwartz TW; Hansen HS; Rosenkilde MM
    Biochem Pharmacol; 2016 Nov; 119():66-75. PubMed ID: 27569424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained wash-resistant receptor activation responses of GPR119 agonists.
    Hothersall JD; Bussey CE; Brown AJ; Scott JS; Dale I; Rawlins P
    Eur J Pharmacol; 2015 Sep; 762():430-42. PubMed ID: 26101059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GPR119 agonists 2009-2011.
    Buzard DJ; Lehmann J; Han S; Jones RM
    Pharm Pat Anal; 2012 Jul; 1(3):285-99. PubMed ID: 24236842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of GPR119 receptor activity with endocannabinoid-like lipids.
    Syed SK; Bui HH; Beavers LS; Farb TB; Ficorilli J; Chesterfield AK; Kuo MS; Bokvist K; Barrett DG; Efanov AM
    Am J Physiol Endocrinol Metab; 2012 Dec; 303(12):E1469-78. PubMed ID: 23074242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
    Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
    Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Novel, Structurally Diverse, Small Molecule Modulators of GPR119.
    Nieto A; Fernández-Vega V; Spicer TP; Sturchler E; Adhikari P; Kennedy N; Mandat S; Chase P; Scampavia L; Bannister T; Hodder P; McDonald PH
    Assay Drug Dev Technol; 2018 Jul; 16(5):278-288. PubMed ID: 30019946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parameterization of the GPR119 Receptor Agonist AR231453.
    Hamilton J; Kotsikorou E
    J Comput Chem; 2018 Jan; 39(1):35-41. PubMed ID: 29023843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.